BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment
Retrieved on:
söndag, juni 2, 2024
Perception, Myalgia, LTP, Patient, Berotralstat, Internal medicine, Acne, Cohort (statistics), Cancer, Dermatology, Hereditary angioedema, BioCryst Pharmaceuticals, Human, Liver, Translational medicine, Menstruation, Liver cancer, Virilization, Risk, HAE, Diagnosis, Androgen, Fraunhofer Society, Physician, Congress, EAACI, Tranexamic acid, Pharmaceutical industry
The data were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain.
Key Points:
- The data were presented at the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain.
- “The diagnosis of HAE patients with normal C1-inhibitor is complicated and often delayed by the lack of an easily measurable biochemical marker.
- One patient experienced gastrointestinal symptoms upon initiation, which became milder after the first two weeks and did not lead to treatment discontinuation.
- Additional new results presented at EAACI demonstrate the adverse health outcomes associated with attenuated androgen use as a prophylactic treatment for HAE.